Business Development

Amulet adopts a flexible approach to its business model with the specific intention of enabling it to consider partnership and out-licensing arrangements for both its primary Gastrointestinal-focused programs as well as secondary indications. The company is committed to seeing NORTECH™ technology adopted into the widest possible range of therapeutic applications.

Business Proposition

Our NORTECH™ technology offers potential partners an exciting opportunity underpinned by:

• Strong, unencumbered IP protection
• Established safety profile with significant advantages over existing technologies
• Deep and broad pipeline with a strong GI focus
• Short development horizon from pre-clinical to NDA

Areas for Partner Consideration

• Gastroparesis
• Obesity
• Enteral feeding in critical care patients
• Irritable bowel syndrome
• Functional dyspepsia
• Wounds
• Diabetes therapeutics
• Pain therapeutics
• Glaucoma